3Desgnerre I, Christov C, Mayer M, et al. Clinical heterogeneity of duchenne muscular dystrophy (DMD) : definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS ONE, 2009,4 (2) :04347.
4del Gandio D, Yang Y, Boggs BA, et al. Molecular diagnosis of Duchenne/Becker muscular dystrophy: enhanced detection of dystro- phin gene rearrangements by oligonucleotide array-comparative ge- nomic hybridization. Hum Murat ,2008,29 (9) : 1100-1107.
5El-Bohy AA, Wong BL. The diagnosis of muscular dystrophy. Pedi- atr Ann,2005,34(7) :525-530.
6Madania A,Zarzour H, Jarjour RA, et al. Combination of conven- tional multiplex PCR and quantitative real-time PCR detects large re- arrangements in the dystrophin gene in 59% of Syrian DMD/BM_D patients. Clin Biochem,2010,43 ( 10-11 ) :836-842.
7Manzur AY, Kuntzer T, Pike M, et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev, 2008, ( 1 ) :CD003725.
8Moxley RT 3rd,Pandya S,Ciafaloni E,et al. Change in natural his- tory of Duchenne muscular dystrophy with long-term corticosteroid treatment:implications for management. J Child Neurol, 2010, 25 (9) :1116-1129.
9Biggar WD, Politano L, Harris VA, et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuro- muscul disord ,2004,14 ( 8-9 ) :476-482.
10Spurney CF,Rocha CT,Henricson E,et al. CINRG pilot trial of co- enzyme Q10 in steroid-treated duchenne muscular dystrophy. Muscle Nerve,2011,44(2) :174-178.
